Aruba - Press Releases

SHANGHAI, March 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine. EVM14 is Everest's first internally developed mRNA therapeutic vaccine to receive FDA IND approval, marking a significant milestone in the Company's efforts to develop innovative mRNA therapeutics in oncology.

-- U.S.IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform --

SAN FRANCISCO andSUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter Phase 3 clinical trial (HeriCare-Ovarian01), for platinum-resistant ovarian cancer (PROC) with HER2 expression.

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of aType II variation applicationto the European Medicines Agency (EMA) forsugemalimab. The application seeks approval for the treatment ofpatients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent or sequential platinum-based chemoradiotherapy (CRT). This marks CStone's second regulatory submission for sugemalimab to the EMA, following its initial approval in Europe for metastatic squamous and non-squamous NSCLC in 2024. If this new indication is approved, sugemalimab would address a critical unmet need in stage III NSCLC, where only one PD-L1 antibody is currently approved in Europe. The drug's dual utility in stage III and IV NSCLC could solidify its role as a cornerstoneimmunotherapy in lung cancer.

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.

Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare

HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue of RMB 2.7 billion, representing an 11.2% year-over-year increase. Notably, the company's adjusted net profit reached RMB 17.2 million, a significant 139% growth compared to 2023, driven by ongoing technology enhancements and improvements in operating efficiency.

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the shares of common stock and associated warrants are being offered by the Company. The offering is expected to close on March 25, 2025, subject to satisfaction of customary closing conditions.

SEATTLE, March 24, 2025 /PRNewswire/ -- The surge in online supplement sales has led to a troubling rise in counterfeit products infiltrating e-commerce platforms, deceiving buyers with misleading packaging and false advertising. PurDentix, Bioventra's brand, a well-established name in health and wellness, is issuing a consumer warning regarding unauthorized resellers distributing imitation versions of its product. The company has identified multiple fraudulent listings across online marketplaces, raising concerns about product authenticity and customer safety.

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw), a portal site providing information on state-of-the-art care and age tech in Japan.

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw), a portal site providing information on state-of-the-art care and age tech in Japan.

STOCKHOLM, March 24, 2025 /PRNewswire/ -- The hygiene and health companyEssity will publish its interim report for quarter 1, 2025 on April 24 at approximately 07:00 CET. President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.

STOCKHOLM, March 24, 2025 /PRNewswire/ -- The hygiene and health companyEssity will publish its interim report for quarter 1, 2025 on April 24 at approximately 07:00CET. President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.

MILAN, March 24, 2025 /PRNewswire/ -- Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has received CE Mark approval for its AlphaDBS device, a next-generation closed-loop DBS system that dynamically adjusts stimulation based on real-time brain signals. This approval enables the company to commercialize AlphaDBS in Europe, bringing an innovative treatment option to patients living with Parkinson's disease and other neurological disorders.

MILAN, 24 mars 2025 /PRNewswire/ -- Newronika, leader de la neuromodulation et de la technologie de stimulation crbrale profonde (SCP) adaptative, a annonc aujourd'hui avoir reu l'approbation du marquage CE pour son dispositif AlphaDBS, un systme de SCP de nouvelle gnration fonctionnant en boucle ferme, et qui ajuste dynamiquement la stimulation en fonction des signaux crbraux en temps rel. Cette approbation permet l'entreprise de commercialiser AlphaDBS en Europe, offrant ainsi une option thrapeutique innovante aux patients atteints de la maladie de Parkinson et d'autres troubles neurologiques.

MAILAND, 24. Mrz 2025 /PRNewswire/ -- Newronika, ein fhrendes Unternehmen im Bereich der Neuromodulation und adaptiven Tiefenhirnstimulation (THS), gab heute bekannt, dass es die CE-Kennzeichnung fr sein AlphaDBS-Gert erhalten hat, ein THS-System der nchsten Generation mit geschlossenem Regelkreis, das die Stimulation dynamisch auf der Grundlage von Echtzeit-Gehirnsignalen anpasst. Diese Zulassung ermglicht es dem Unternehmen, AlphaDBS in Europa zu vermarkten und Patienten mit Parkinson und anderen neurologischen Erkrankungen eine innovative Behandlungsmglichkeit zu bieten.

Rise in prevalence of cardiovascular diseases (CVDS), expanding applications in pain management & fever reduction, and government & healthcare initiatives promoting preventive medicine drive the growth of the global aspirin drugs market.

ARLINGTON, Va., March 21, 2025 /PRNewswire/ -- The U.S. Air Force announced Boeing [NYSE: BA] has been awarded a contract to design, build and deliver its next-generation fighter aircraft.

Dernire chance de rejoindre le meilleur programme de pr-acclration europen pour les entrepreneurs del'UE, avec des prix spciaux pour les innovateurs des principales rgions mergentes.

Prominent guests to include Savannah Guthrie, Lee Greenwood, Gary Sinese, widow of country superstar Toby Keith, Cowboys legends, other national, state and local elected leaders

WILMINGTON, N.C., March 21, 2025 /PRNewswire/ -- The North Carolina Insurance Underwriting Association (NCIUA) reaffirmed its commitment to building a stronger, storm-ready North Carolina today at an event celebrating a major milestone: more than 15,000 FORTIFIED Roof designations statewide. The event also recognized the individuals and organizations instrumental in bringing the FORTIFIED program to North Carolina's coastal communities.

PARK CITY, Utah, March 21, 2025 /PRNewswire/ -- As one of the most sought-after mountain destinations in the United States, Park City, Utah continues to captivate buyers looking for luxury homes that combine the thrill of outdoor recreation with the comfort of upscale living. With its world-renowned ski resorts, exclusive neighborhoods, and high demand for vacation homes, Park City's real estate market remains a hotspot for both seasonal buyers and investors, according to Emerald Wave Enterprises.

TAMPA, Fla., March 22, 2025 /PRNewswire/ -- Leisure Investment Properties Group (LIPG) proudly announces the release of its 2025 RV & MHP Investment Report and 2025 Hospitality Investment Report, offering critical insights into two of the fastest-growing real estate sectors. These comprehensive reports provide in-depth market data, key investment trends, and forecasts to help investors make informed decisions.

DAHEJ, India, March 24, 2025 /PRNewswire/ -- Gulbrandsen, a global leader in the production of specialty polyethylene waxes and polymers, today announced its plans to build additional polyethylene wax manufacturing capacity and a new functional polymers plant at its site in Dahej, India.

LONDON, March 24, 2025 /PRNewswire/ -- Markel, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced that it has made three internal promotions and hired a Technical Claims Lead to further enhance its award-winning Wholesale Claims service for brokers, insureds and trading partners.